Changes

CLL Tables: Regions of Recurrent Copy Number Change and CN-LOH (view source)

Revision as of 22:20, 7 November 2020

222 bytes added , 22:20, 7 November 2020

Minor style improvements

Line 287: Line 287:

Abbreviations: CNA = copy number aberration; CLL = chronic lymphocytic leukemia; CN-LOH = copy-neutral loss-of-heterozygosity

−

'''Table 2. Recurring regions of CN-LOH in CLL'''

+

'''Table 2 - Recurring regions of CN-LOH in CLL.''' Table derived from Chun et al., 2018 [PMID 30554732] with permission from Cancer Genetics.

{| class="wikitable"

|'''CN-LOH'''

Line 299: Line 300:

|Biallelic deletion of 13q

|Established (1)

−

|<ref name=":13">{{Cite journal|last=Hagenkord|first=Jill M.|last2=Monzon|first2=Federico A.|last3=Kash|first3=Shera F.|last4=Lilleberg|first4=Stan|last5=Xie|first5=Qingmei|last6=Kant|first6=Jeffrey A.|date=2010-03|title=Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays|url=https://pubmed.ncbi.nlm.nih.gov/20075210|journal=The Journal of molecular diagnostics: JMD|volume=12|issue=2|pages=184–196|doi=10.2353/jmoldx.2010.090118|issn=1943-7811|pmc=2871725|pmid=20075210}}</ref><ref>{{Cite journal|last=Pfeifer|first=Dietmar|last2=Pantic|first2=Milena|last3=Skatulla|first3=Ilona|last4=Rawluk|first4=Justyna|last5=Kreutz|first5=Clemens|last6=Martens|first6=Uwe M.|last7=Fisch|first7=Paul|last8=Timmer|first8=Jens|last9=Veelken|first9=Hendrik|date=2007-02-01|title=Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays|url=https://pubmed.ncbi.nlm.nih.gov/17053054|journal=Blood|volume=109|issue=3|pages=1202–1210|doi=10.1182/blood-2006-07-034256|issn=0006-4971|pmid=17053054}}</ref><ref name=":14">{{Cite journal|last=Edelmann|first=Jennifer|last2=Holzmann|first2=Karlheinz|last3=Miller|first3=Florian|last4=Winkler|first4=Dirk|last5=Bühler|first5=Andreas|last6=Zenz|first6=Thorsten|last7=Bullinger|first7=Lars|last8=Kühn|first8=Michael W. M.|last9=Gerhardinger|first9=Andreas|date=2012-12-06|title=High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations|url=https://pubmed.ncbi.nlm.nih.gov/23047824|journal=Blood|volume=120|issue=24|pages=4783–4794|doi=10.1182/blood-2012-04-423517|issn=1528-0020|pmid=23047824}}</ref><ref>{{Cite journal|last=Grygalewicz|first=Beata|last2=Woroniecka|first2=Renata|last3=Rygier|first3=Jolanta|last4=Borkowska|first4=Klaudia|last5=Rzepecka|first5=Iwona|last6=Łukasik|first6=Martyna|last7=Budziłowska|first7=Agnieszka|last8=Rymkiewicz|first8=Grzegorz|last9=Błachnio|first9=Katarzyna|date=2016|title=Monoallelic and biallelic deletions of 13q14 in a group of CLL/SLL patients investigated by CGH Haematological Cancer and SNP array (8x60K)|url=https://pubmed.ncbi.nlm.nih.gov/26740820|journal=Molecular Cytogenetics|volume=9|pages=1|doi=10.1186/s13039-015-0212-x|issn=1755-8166|pmc=4702365|pmid=26740820}}</ref><ref>{{Cite journal|last=Gunnarsson|first=Rebeqa|last2=Mansouri|first2=Larry|last3=Isaksson|first3=Anders|last4=Göransson|first4=Hanna|last5=Cahill|first5=Nicola|last6=Jansson|first6=Mattias|last7=Rasmussen|first7=Markus|last8=Lundin|first8=Jeanette|last9=Norin|first9=Stefan|date=2011-08|title=Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/21546498|journal=Haematologica|volume=96|issue=8|pages=1161–1169|doi=10.3324/haematol.2010.039768|issn=1592-8721|pmc=3148910|pmid=21546498}}</ref><ref name=":15">{{Cite journal|last=Parker|first=H.|last2=Rose-Zerilli|first2=M. J. J.|last3=Parker|first3=A.|last4=Chaplin|first4=T.|last5=Wade|first5=R.|last6=Gardiner|first6=A.|last7=Griffiths|first7=M.|last8=Collins|first8=A.|last9=Young|first9=B. D.|date=2011-03|title=13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/21151023|journal=Leukemia|volume=25|issue=3|pages=489–497|doi=10.1038/leu.2010.288|issn=1476-5551|pmid=21151023}}</ref><ref>{{Cite journal|last=Lehmann|first=Sören|last2=Ogawa|first2=Seishi|last3=Raynaud|first3=Sophie D.|last4=Sanada|first4=Masashi|last5=Nannya|first5=Yasuhito|last6=Ticchioni|first6=Michel|last7=Bastard|first7=Christian|last8=Kawamata|first8=Norihiko|last9=Koeffler|first9=H. Phillip|date=2008-03-15|title=Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/18246537|journal=Cancer|volume=112|issue=6|pages=1296–1305|doi=10.1002/cncr.23270|issn=0008-543X|pmid=18246537}}</ref><ref>{{Cite journal|last=Ouillette|first=Peter|last2=Collins|first2=Roxane|last3=Shakhan|first3=Sajid|last4=Li|first4=Jinghui|last5=Li|first5=Cheng|last6=Shedden|first6=Kerby|last7=Malek|first7=Sami N.|date=2011-11-01|title=The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/21890456|journal=Clinical Cancer Research: An Official Journal of the American Association for Cancer Research|volume=17|issue=21|pages=6778–6790|doi=10.1158/1078-0432.CCR-11-0785|issn=1078-0432|pmc=3207001|pmid=21890456}}</ref>

+

|<ref name=":13">{{Cite journal|last=Hagenkord|first=Jill M.|last2=Monzon|first2=Federico A.|last3=Kash|first3=Shera F.|last4=Lilleberg|first4=Stan|last5=Xie|first5=Qingmei|last6=Kant|first6=Jeffrey A.|date=2010-03|title=Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays|url=https://pubmed.ncbi.nlm.nih.gov/20075210|journal=The Journal of molecular diagnostics: JMD|volume=12|issue=2|pages=184–196|doi=10.2353/jmoldx.2010.090118|issn=1943-7811|pmc=2871725|pmid=20075210}}</ref> <ref>{{Cite journal|last=Pfeifer|first=Dietmar|last2=Pantic|first2=Milena|last3=Skatulla|first3=Ilona|last4=Rawluk|first4=Justyna|last5=Kreutz|first5=Clemens|last6=Martens|first6=Uwe M.|last7=Fisch|first7=Paul|last8=Timmer|first8=Jens|last9=Veelken|first9=Hendrik|date=2007-02-01|title=Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays|url=https://pubmed.ncbi.nlm.nih.gov/17053054|journal=Blood|volume=109|issue=3|pages=1202–1210|doi=10.1182/blood-2006-07-034256|issn=0006-4971|pmid=17053054}}</ref> <ref name=":14">{{Cite journal|last=Edelmann|first=Jennifer|last2=Holzmann|first2=Karlheinz|last3=Miller|first3=Florian|last4=Winkler|first4=Dirk|last5=Bühler|first5=Andreas|last6=Zenz|first6=Thorsten|last7=Bullinger|first7=Lars|last8=Kühn|first8=Michael W. M.|last9=Gerhardinger|first9=Andreas|date=2012-12-06|title=High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations|url=https://pubmed.ncbi.nlm.nih.gov/23047824|journal=Blood|volume=120|issue=24|pages=4783–4794|doi=10.1182/blood-2012-04-423517|issn=1528-0020|pmid=23047824}}</ref> <ref>{{Cite journal|last=Grygalewicz|first=Beata|last2=Woroniecka|first2=Renata|last3=Rygier|first3=Jolanta|last4=Borkowska|first4=Klaudia|last5=Rzepecka|first5=Iwona|last6=Łukasik|first6=Martyna|last7=Budziłowska|first7=Agnieszka|last8=Rymkiewicz|first8=Grzegorz|last9=Błachnio|first9=Katarzyna|date=2016|title=Monoallelic and biallelic deletions of 13q14 in a group of CLL/SLL patients investigated by CGH Haematological Cancer and SNP array (8x60K)|url=https://pubmed.ncbi.nlm.nih.gov/26740820|journal=Molecular Cytogenetics|volume=9|pages=1|doi=10.1186/s13039-015-0212-x|issn=1755-8166|pmc=4702365|pmid=26740820}}</ref> <ref>{{Cite journal|last=Gunnarsson|first=Rebeqa|last2=Mansouri|first2=Larry|last3=Isaksson|first3=Anders|last4=Göransson|first4=Hanna|last5=Cahill|first5=Nicola|last6=Jansson|first6=Mattias|last7=Rasmussen|first7=Markus|last8=Lundin|first8=Jeanette|last9=Norin|first9=Stefan|date=2011-08|title=Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/21546498|journal=Haematologica|volume=96|issue=8|pages=1161–1169|doi=10.3324/haematol.2010.039768|issn=1592-8721|pmc=3148910|pmid=21546498}}</ref> <ref name=":15">{{Cite journal|last=Parker|first=H.|last2=Rose-Zerilli|first2=M. J. J.|last3=Parker|first3=A.|last4=Chaplin|first4=T.|last5=Wade|first5=R.|last6=Gardiner|first6=A.|last7=Griffiths|first7=M.|last8=Collins|first8=A.|last9=Young|first9=B. D.|date=2011-03|title=13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/21151023|journal=Leukemia|volume=25|issue=3|pages=489–497|doi=10.1038/leu.2010.288|issn=1476-5551|pmid=21151023}}</ref> <ref>{{Cite journal|last=Lehmann|first=Sören|last2=Ogawa|first2=Seishi|last3=Raynaud|first3=Sophie D.|last4=Sanada|first4=Masashi|last5=Nannya|first5=Yasuhito|last6=Ticchioni|first6=Michel|last7=Bastard|first7=Christian|last8=Kawamata|first8=Norihiko|last9=Koeffler|first9=H. Phillip|date=2008-03-15|title=Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/18246537|journal=Cancer|volume=112|issue=6|pages=1296–1305|doi=10.1002/cncr.23270|issn=0008-543X|pmid=18246537}}</ref> <ref>{{Cite journal|last=Ouillette|first=Peter|last2=Collins|first2=Roxane|last3=Shakhan|first3=Sajid|last4=Li|first4=Jinghui|last5=Li|first5=Cheng|last6=Shedden|first6=Kerby|last7=Malek|first7=Sami N.|date=2011-11-01|title=The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/21890456|journal=Clinical Cancer Research: An Official Journal of the American Association for Cancer Research|volume=17|issue=21|pages=6778–6790|doi=10.1158/1078-0432.CCR-11-0785|issn=1078-0432|pmc=3207001|pmid=21890456}}</ref>

|-

|17p13

Line 305: Line 306:

|Homozygous ''TP53'' mutations

|Established (1)

−

|<ref name=":13" /><ref name=":14" /><ref name=":16">{{Cite journal|last=Stevens-Kroef|first=Marian Jpl|last2=van den Berg|first2=Eva|last3=Olde Weghuis|first3=Daniel|last4=Geurts van Kessel|first4=Ad|last5=Pfundt|first5=Rolph|last6=Linssen-Wiersma|first6=Matty|last7=Benjamins|first7=Marloes|last8=Dijkhuizen|first8=Trijnie|last9=Groenen|first9=Patricia Jta|date=2014-01-09|title=Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using microarray-based genomic profiling|url=https://pubmed.ncbi.nlm.nih.gov/24401281|journal=Molecular Cytogenetics|volume=7|issue=1|pages=3|doi=10.1186/1755-8166-7-3|issn=1755-8166|pmc=3905918|pmid=24401281}}</ref><ref name=":15" /><ref>{{Cite journal|last=Saddler|first=Chris|last2=Ouillette|first2=Peter|last3=Kujawski|first3=Lisa|last4=Shangary|first4=Sanjeev|last5=Talpaz|first5=Moshe|last6=Kaminski|first6=Mark|last7=Erba|first7=Harry|last8=Shedden|first8=Kerby|last9=Wang|first9=Shaomeng|date=2008-02-01|title=Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/17971485|journal=Blood|volume=111|issue=3|pages=1584–1593|doi=10.1182/blood-2007-09-112698|issn=0006-4971|pmid=17971485}}</ref>

+

|<ref name=":13" /> <ref name=":14" /> <ref name=":16">{{Cite journal|last=Stevens-Kroef|first=Marian Jpl|last2=van den Berg|first2=Eva|last3=Olde Weghuis|first3=Daniel|last4=Geurts van Kessel|first4=Ad|last5=Pfundt|first5=Rolph|last6=Linssen-Wiersma|first6=Matty|last7=Benjamins|first7=Marloes|last8=Dijkhuizen|first8=Trijnie|last9=Groenen|first9=Patricia Jta|date=2014-01-09|title=Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using microarray-based genomic profiling|url=https://pubmed.ncbi.nlm.nih.gov/24401281|journal=Molecular Cytogenetics|volume=7|issue=1|pages=3|doi=10.1186/1755-8166-7-3|issn=1755-8166|pmc=3905918|pmid=24401281}}</ref> <ref name=":15" /> <ref>{{Cite journal|last=Saddler|first=Chris|last2=Ouillette|first2=Peter|last3=Kujawski|first3=Lisa|last4=Shangary|first4=Sanjeev|last5=Talpaz|first5=Moshe|last6=Kaminski|first6=Mark|last7=Erba|first7=Harry|last8=Shedden|first8=Kerby|last9=Wang|first9=Shaomeng|date=2008-02-01|title=Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/17971485|journal=Blood|volume=111|issue=3|pages=1584–1593|doi=10.1182/blood-2007-09-112698|issn=0006-4971|pmid=17971485}}</ref>

|-

|11q13-qter

Line 311: Line 312:

|Monoallelic ''ATM'' deletion

|Suspected (2)

−

|<ref name=":14" /><ref name=":15" />

+

|<ref name=":14" /> <ref name=":15" />

|-

|20q11

Line 317: Line 318:

|None

|N/A (3)

−

|<ref name=":16" /><ref>{{Cite journal|last=Pei|first=Jianming|last2=Robu|first2=Valentin|last3=Feder|first3=Madelyn|last4=Cheung|first4=Mitchell|last5=Neumann-Domer|first5=Erin|last6=Talarchek|first6=Jacqueline|last7=Dulaimi|first7=Essel|last8=Millenson|first8=Michael M.|last9=Testa|first9=Joseph R.|date=2014-03|title=Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/24704113|journal=Cancer Genetics|volume=207|issue=3|pages=98–102|doi=10.1016/j.cancergen.2014.02.005|issn=2210-7762|pmc=4010307|pmid=24704113}}</ref>

+

|<ref name=":16" /> <ref>{{Cite journal|last=Pei|first=Jianming|last2=Robu|first2=Valentin|last3=Feder|first3=Madelyn|last4=Cheung|first4=Mitchell|last5=Neumann-Domer|first5=Erin|last6=Talarchek|first6=Jacqueline|last7=Dulaimi|first7=Essel|last8=Millenson|first8=Michael M.|last9=Testa|first9=Joseph R.|date=2014-03|title=Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/24704113|journal=Cancer Genetics|volume=207|issue=3|pages=98–102|doi=10.1016/j.cancergen.2014.02.005|issn=2210-7762|pmc=4010307|pmid=24704113}}</ref>

|-

|1p36

Line 323: Line 324:

|None

|N/A (3)

−

|<ref name=":14" /><ref>{{Cite journal|last=Xu|first=Xinjie|last2=Johnson|first2=Eric B.|last3=Leverton|first3=Lisa|last4=Arthur|first4=Ashley|last5=Watson|first5=Quinn|last6=Chang|first6=Faye L.|last7=Raca|first7=Gordana|last8=Laffin|first8=Jennifer J.|date=2013-09|title=The advantage of using SNP array in clinical testing for hematological malignancies--a comparative study of three genetic testing methods|url=https://pubmed.ncbi.nlm.nih.gov/24269304|journal=Cancer Genetics|volume=206|issue=9-10|pages=317–326|doi=10.1016/j.cancergen.2013.09.001|issn=2210-7762|pmid=24269304}}</ref>

+

|<ref name=":14" /> <ref>{{Cite journal|last=Xu|first=Xinjie|last2=Johnson|first2=Eric B.|last3=Leverton|first3=Lisa|last4=Arthur|first4=Ashley|last5=Watson|first5=Quinn|last6=Chang|first6=Faye L.|last7=Raca|first7=Gordana|last8=Laffin|first8=Jennifer J.|date=2013-09|title=The advantage of using SNP array in clinical testing for hematological malignancies--a comparative study of three genetic testing methods|url=https://pubmed.ncbi.nlm.nih.gov/24269304|journal=Cancer Genetics|volume=206|issue=9-10|pages=317–326|doi=10.1016/j.cancergen.2013.09.001|issn=2210-7762|pmid=24269304}}</ref>

|}

<nowiki>*</nowiki>Level 1: present in WHO classification or professional practice guidelines; Level 2: recurrent in well-powered studies with suspected clinical significance; Level 3: recurrent, but uncertain prognostic significance

−

+

'''Table 3 - Recurrent mutated genes in CLL.''' Table derived from Chun et al., 2018 [PMID 30554732] with permission from Cancer Genetics.

−

'''Table 3. Recurrent mutated genes in CLL'''

{| class="wikitable"

|'''Gene'''

Line 348: Line 348:

|Established (1)

|Associated with unmut''IGHV'' and 11q-; Candidate driver gene

−

|<ref name=":17">{{Cite journal|last=Wierda|first=William G.|last2=Zelenetz|first2=Andrew D.|last3=Gordon|first3=Leo I.|last4=Abramson|first4=Jeremy S.|last5=Advani|first5=Ranjana H.|last6=Andreadis|first6=C. Babis|last7=Bartlett|first7=Nancy|last8=Byrd|first8=John C.|last9=Caimi|first9=Paolo|date=03 2017|title=NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017|url=https://pubmed.ncbi.nlm.nih.gov/28275031|journal=Journal of the National Comprehensive Cancer Network: JNCCN|volume=15|issue=3|pages=293–311|doi=10.6004/jnccn.2017.0030|issn=1540-1413|pmid=28275031}}</ref><ref name=":18">{{Cite journal|last=Campregher|first=Paulo Vidal|last2=Hamerschlak|first2=Nelson|date=2014-08|title=Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice|url=https://pubmed.ncbi.nlm.nih.gov/24548608|journal=Clinical Lymphoma, Myeloma & Leukemia|volume=14|issue=4|pages=271–276|doi=10.1016/j.clml.2013.12.016|issn=2152-2669|pmid=24548608}}</ref>

+

|<ref name=":17">{{Cite journal|last=Wierda|first=William G.|last2=Zelenetz|first2=Andrew D.|last3=Gordon|first3=Leo I.|last4=Abramson|first4=Jeremy S.|last5=Advani|first5=Ranjana H.|last6=Andreadis|first6=C. Babis|last7=Bartlett|first7=Nancy|last8=Byrd|first8=John C.|last9=Caimi|first9=Paolo|date=03 2017|title=NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017|url=https://pubmed.ncbi.nlm.nih.gov/28275031|journal=Journal of the National Comprehensive Cancer Network: JNCCN|volume=15|issue=3|pages=293–311|doi=10.6004/jnccn.2017.0030|issn=1540-1413|pmid=28275031}}</ref> <ref name=":18">{{Cite journal|last=Campregher|first=Paulo Vidal|last2=Hamerschlak|first2=Nelson|date=2014-08|title=Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice|url=https://pubmed.ncbi.nlm.nih.gov/24548608|journal=Clinical Lymphoma, Myeloma & Leukemia|volume=14|issue=4|pages=271–276|doi=10.1016/j.clml.2013.12.016|issn=2152-2669|pmid=24548608}}</ref>

|-

|''[[BIRC3]]''

Line 360: Line 360:

|Established (1)

|In ~25% of fludarabine-refractory CLL; Candidate driver gene

−

|<ref name=":19">{{Cite journal|last=Strefford|first=Jonathan C.|date=2015-04|title=The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications|url=https://pubmed.ncbi.nlm.nih.gov/25496136|journal=British Journal of Haematology|volume=169|issue=1|pages=14–31|doi=10.1111/bjh.13254|issn=1365-2141|pmid=25496136}}</ref><ref>{{Cite journal|last=Alsolami|first=Reem|last2=Knight|first2=Samantha Jl|last3=Schuh|first3=Anna|date=2013-06-01|title=Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?|url=https://pubmed.ncbi.nlm.nih.gov/24611071|journal=Personalized Medicine|volume=10|issue=4|pages=361–376|doi=10.2217/pme.13.33|issn=1741-0541|pmc=3943176|pmid=24611071}}</ref><ref name=":20">{{Cite journal|last=Baliakas|first=P.|last2=Hadzidimitriou|first2=A.|last3=Sutton|first3=L.-A.|last4=Rossi|first4=D.|last5=Minga|first5=E.|last6=Villamor|first6=N.|last7=Larrayoz|first7=M.|last8=Kminkova|first8=J.|last9=Agathangelidis|first9=A.|date=2015-02|title=Recurrent mutations refine prognosis in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/24943832|journal=Leukemia|volume=29|issue=2|pages=329–336|doi=10.1038/leu.2014.196|issn=1476-5551|pmid=24943832}}</ref><ref name=":21">{{Cite journal|last=Rossi|first=Davide|last2=Rasi|first2=Silvia|last3=Spina|first3=Valeria|last4=Bruscaggin|first4=Alessio|last5=Monti|first5=Sara|last6=Ciardullo|first6=Carmela|last7=Deambrogi|first7=Clara|last8=Khiabanian|first8=Hossein|last9=Serra|first9=Roberto|date=2013-02-21|title=Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/23243274|journal=Blood|volume=121|issue=8|pages=1403–1412|doi=10.1182/blood-2012-09-458265|issn=1528-0020|pmc=3578955|pmid=23243274}}</ref>

+

|<ref name=":19">{{Cite journal|last=Strefford|first=Jonathan C.|date=2015-04|title=The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications|url=https://pubmed.ncbi.nlm.nih.gov/25496136|journal=British Journal of Haematology|volume=169|issue=1|pages=14–31|doi=10.1111/bjh.13254|issn=1365-2141|pmid=25496136}}</ref> <ref>{{Cite journal|last=Alsolami|first=Reem|last2=Knight|first2=Samantha Jl|last3=Schuh|first3=Anna|date=2013-06-01|title=Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?|url=https://pubmed.ncbi.nlm.nih.gov/24611071|journal=Personalized Medicine|volume=10|issue=4|pages=361–376|doi=10.2217/pme.13.33|issn=1741-0541|pmc=3943176|pmid=24611071}}</ref> <ref name=":20">{{Cite journal|last=Baliakas|first=P.|last2=Hadzidimitriou|first2=A.|last3=Sutton|first3=L.-A.|last4=Rossi|first4=D.|last5=Minga|first5=E.|last6=Villamor|first6=N.|last7=Larrayoz|first7=M.|last8=Kminkova|first8=J.|last9=Agathangelidis|first9=A.|date=2015-02|title=Recurrent mutations refine prognosis in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/24943832|journal=Leukemia|volume=29|issue=2|pages=329–336|doi=10.1038/leu.2014.196|issn=1476-5551|pmid=24943832}}</ref> <ref name=":21">{{Cite journal|last=Rossi|first=Davide|last2=Rasi|first2=Silvia|last3=Spina|first3=Valeria|last4=Bruscaggin|first4=Alessio|last5=Monti|first5=Sara|last6=Ciardullo|first6=Carmela|last7=Deambrogi|first7=Clara|last8=Khiabanian|first8=Hossein|last9=Serra|first9=Roberto|date=2013-02-21|title=Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/23243274|journal=Blood|volume=121|issue=8|pages=1403–1412|doi=10.1182/blood-2012-09-458265|issn=1528-0020|pmc=3578955|pmid=23243274}}</ref>

|-

|''[[CHD2]]''

Line 370: Line 370:

|N/A (3)

|

−

|<ref name=":19" /><ref>{{Cite journal|last=Rodríguez|first=David|last2=Bretones|first2=Gabriel|last3=Quesada|first3=Víctor|last4=Villamor|first4=Neus|last5=Arango|first5=Javier R.|last6=López-Guillermo|first6=Armando|last7=Ramsay|first7=Andrew J.|last8=Baumann|first8=Tycho|last9=Quirós|first9=Pedro M.|date=2015-07-09|title=Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/26031915|journal=Blood|volume=126|issue=2|pages=195–202|doi=10.1182/blood-2014-10-604959|issn=1528-0020|pmid=26031915}}</ref>

+

|<ref name=":19" /> <ref>{{Cite journal|last=Rodríguez|first=David|last2=Bretones|first2=Gabriel|last3=Quesada|first3=Víctor|last4=Villamor|first4=Neus|last5=Arango|first5=Javier R.|last6=López-Guillermo|first6=Armando|last7=Ramsay|first7=Andrew J.|last8=Baumann|first8=Tycho|last9=Quirós|first9=Pedro M.|date=2015-07-09|title=Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/26031915|journal=Blood|volume=126|issue=2|pages=195–202|doi=10.1182/blood-2014-10-604959|issn=1528-0020|pmid=26031915}}</ref>

|-

|''[[FBXW7]]''

Line 392: Line 392:

|Suspected (2)

|Candidate driver gene

−

|<ref name=":20" /><ref name=":21" /><ref name=":22">{{Cite journal|last=Filip|first=Agata A.|date=2013-09|title=New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works|url=https://pubmed.ncbi.nlm.nih.gov/23343182|journal=Leukemia & Lymphoma|volume=54|issue=9|pages=1876–1881|doi=10.3109/10428194.2013.769049|issn=1029-2403|pmid=23343182}}</ref>

+

|<ref name=":20" /> <ref name=":21" /> <ref name=":22">{{Cite journal|last=Filip|first=Agata A.|date=2013-09|title=New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works|url=https://pubmed.ncbi.nlm.nih.gov/23343182|journal=Leukemia & Lymphoma|volume=54|issue=9|pages=1876–1881|doi=10.3109/10428194.2013.769049|issn=1029-2403|pmid=23343182}}</ref>

|-

|''[[NOTCH1]]''

Line 408: Line 408:

|Established (1)

|Associated with +12; Candidate driver gene

−

|<ref>{{Cite journal|last=Nabhan|first=Chadi|last2=Raca|first2=Gordana|last3=Wang|first3=Y. Lynn|date=2015-10|title=Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era|url=https://pubmed.ncbi.nlm.nih.gov/26181643|journal=JAMA oncology|volume=1|issue=7|pages=965–974|doi=10.1001/jamaoncol.2015.0779|issn=2374-2445|pmid=26181643}}</ref><ref name=":18" /><ref name=":21" /><ref>{{Cite journal|last=Balatti|first=Veronica|last2=Bottoni|first2=Arianna|last3=Palamarchuk|first3=Alexey|last4=Alder|first4=Hansjuerg|last5=Rassenti|first5=Laura Z.|last6=Kipps|first6=Thomas J.|last7=Pekarsky|first7=Yuri|last8=Croce|first8=Carlo M.|date=2012-01-12|title=NOTCH1 mutations in CLL associated with trisomy 12|url=https://pubmed.ncbi.nlm.nih.gov/22086416|journal=Blood|volume=119|issue=2|pages=329–331|doi=10.1182/blood-2011-10-386144|issn=1528-0020|pmc=3257004|pmid=22086416}}</ref><ref>{{Cite journal|last=Del Giudice|first=Ilaria|last2=Rossi|first2=Davide|last3=Chiaretti|first3=Sabina|last4=Marinelli|first4=Marilisa|last5=Tavolaro|first5=Simona|last6=Gabrielli|first6=Sara|last7=Laurenti|first7=Luca|last8=Marasca|first8=Roberto|last9=Rasi|first9=Silvia|date=2012-03|title=NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL|url=https://pubmed.ncbi.nlm.nih.gov/22207691|journal=Haematologica|volume=97|issue=3|pages=437–441|doi=10.3324/haematol.2011.060129|issn=1592-8721|pmc=3291600|pmid=22207691}}</ref>

+

|<ref>{{Cite journal|last=Nabhan|first=Chadi|last2=Raca|first2=Gordana|last3=Wang|first3=Y. Lynn|date=2015-10|title=Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era|url=https://pubmed.ncbi.nlm.nih.gov/26181643|journal=JAMA oncology|volume=1|issue=7|pages=965–974|doi=10.1001/jamaoncol.2015.0779|issn=2374-2445|pmid=26181643}}</ref> <ref name=":18" /> <ref name=":21" /> <ref>{{Cite journal|last=Balatti|first=Veronica|last2=Bottoni|first2=Arianna|last3=Palamarchuk|first3=Alexey|last4=Alder|first4=Hansjuerg|last5=Rassenti|first5=Laura Z.|last6=Kipps|first6=Thomas J.|last7=Pekarsky|first7=Yuri|last8=Croce|first8=Carlo M.|date=2012-01-12|title=NOTCH1 mutations in CLL associated with trisomy 12|url=https://pubmed.ncbi.nlm.nih.gov/22086416|journal=Blood|volume=119|issue=2|pages=329–331|doi=10.1182/blood-2011-10-386144|issn=1528-0020|pmc=3257004|pmid=22086416}}</ref> <ref>{{Cite journal|last=Del Giudice|first=Ilaria|last2=Rossi|first2=Davide|last3=Chiaretti|first3=Sabina|last4=Marinelli|first4=Marilisa|last5=Tavolaro|first5=Simona|last6=Gabrielli|first6=Sara|last7=Laurenti|first7=Luca|last8=Marasca|first8=Roberto|last9=Rasi|first9=Silvia|date=2012-03|title=NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL|url=https://pubmed.ncbi.nlm.nih.gov/22207691|journal=Haematologica|volume=97|issue=3|pages=437–441|doi=10.3324/haematol.2011.060129|issn=1592-8721|pmc=3291600|pmid=22207691}}</ref>

|-

|''[[POT1]]''

Line 420: Line 420:

|Suspected (2)

|Associated with familial CLL

−

|<ref>{{Cite journal|last=Herling|first=Carmen Diana|last2=Klaumünzer|first2=Marion|last3=Rocha|first3=Cristiano Krings|last4=Altmüller|first4=Janine|last5=Thiele|first5=Holger|last6=Bahlo|first6=Jasmin|last7=Kluth|first7=Sandra|last8=Crispatzu|first8=Giuliano|last9=Herling|first9=Marco|date=07 21, 2016|title=Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy|url=https://pubmed.ncbi.nlm.nih.gov/27226433|journal=Blood|volume=128|issue=3|pages=395–404|doi=10.1182/blood-2016-01-691550|issn=1528-0020|pmid=27226433}}</ref><ref>{{Cite journal|last=Ramsay|first=Andrew J.|last2=Quesada|first2=Víctor|last3=Foronda|first3=Miguel|last4=Conde|first4=Laura|last5=Martínez-Trillos|first5=Alejandra|last6=Villamor|first6=Neus|last7=Rodríguez|first7=David|last8=Kwarciak|first8=Agnieszka|last9=Garabaya|first9=Cecilia|date=2013-05|title=POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/23502782|journal=Nature Genetics|volume=45|issue=5|pages=526–530|doi=10.1038/ng.2584|issn=1546-1718|pmid=23502782}}</ref><ref>{{Cite journal|last=Speedy|first=Helen E.|last2=Kinnersley|first2=Ben|last3=Chubb|first3=Daniel|last4=Broderick|first4=Peter|last5=Law|first5=Philip J.|last6=Litchfield|first6=Kevin|last7=Jayne|first7=Sandrine|last8=Dyer|first8=Martin J. S.|last9=Dearden|first9=Claire|date=11 10, 2016|title=Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/27528712|journal=Blood|volume=128|issue=19|pages=2319–2326|doi=10.1182/blood-2016-01-695692|issn=1528-0020|pmc=5271173|pmid=27528712}}</ref>

+

|<ref>{{Cite journal|last=Herling|first=Carmen Diana|last2=Klaumünzer|first2=Marion|last3=Rocha|first3=Cristiano Krings|last4=Altmüller|first4=Janine|last5=Thiele|first5=Holger|last6=Bahlo|first6=Jasmin|last7=Kluth|first7=Sandra|last8=Crispatzu|first8=Giuliano|last9=Herling|first9=Marco|date=07 21, 2016|title=Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy|url=https://pubmed.ncbi.nlm.nih.gov/27226433|journal=Blood|volume=128|issue=3|pages=395–404|doi=10.1182/blood-2016-01-691550|issn=1528-0020|pmid=27226433}}</ref> <ref>{{Cite journal|last=Ramsay|first=Andrew J.|last2=Quesada|first2=Víctor|last3=Foronda|first3=Miguel|last4=Conde|first4=Laura|last5=Martínez-Trillos|first5=Alejandra|last6=Villamor|first6=Neus|last7=Rodríguez|first7=David|last8=Kwarciak|first8=Agnieszka|last9=Garabaya|first9=Cecilia|date=2013-05|title=POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/23502782|journal=Nature Genetics|volume=45|issue=5|pages=526–530|doi=10.1038/ng.2584|issn=1546-1718|pmid=23502782}}</ref> <ref>{{Cite journal|last=Speedy|first=Helen E.|last2=Kinnersley|first2=Ben|last3=Chubb|first3=Daniel|last4=Broderick|first4=Peter|last5=Law|first5=Philip J.|last6=Litchfield|first6=Kevin|last7=Jayne|first7=Sandrine|last8=Dyer|first8=Martin J. S.|last9=Dearden|first9=Claire|date=11 10, 2016|title=Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/27528712|journal=Blood|volume=128|issue=19|pages=2319–2326|doi=10.1182/blood-2016-01-695692|issn=1528-0020|pmc=5271173|pmid=27528712}}</ref>

|-

|''[[SF3B1]]''

Line 430: Line 430:

|Established (1)

|Enriched in patients with del(11q) and unmut''IGHV''; Candidate driver gene for disease progression

−

|<ref name=":20" /><ref name=":21" /><ref>{{Cite journal|last=Mitsui|first=Takeki|last2=Koiso|first2=Hiromi|last3=Nakahashi|first3=Hirotaka|last4=Saitoh|first4=Akio|last5=Shimizu|first5=Hiroaki|last6=Ishizaki|first6=Takuma|last7=Ogawa|first7=Yoshiyuki|last8=Takizawa|first8=Makiko|last9=Yokohama|first9=Akihiko|date=2016-02|title=SF3B1 and IGHV gene mutation status predict poor prognosis in Japanese CLL patients|url=https://pubmed.ncbi.nlm.nih.gov/26588928|journal=International Journal of Hematology|volume=103|issue=2|pages=219–226|doi=10.1007/s12185-015-1912-z|issn=1865-3774|pmid=26588928}}</ref><ref>{{Cite journal|last=Quesada|first=Víctor|last2=Conde|first2=Laura|last3=Villamor|first3=Neus|last4=Ordóñez|first4=Gonzalo R.|last5=Jares|first5=Pedro|last6=Bassaganyas|first6=Laia|last7=Ramsay|first7=Andrew J.|last8=Beà|first8=Sílvia|last9=Pinyol|first9=Magda|date=2011-12-11|title=Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/22158541|journal=Nature Genetics|volume=44|issue=1|pages=47–52|doi=10.1038/ng.1032|issn=1546-1718|pmid=22158541}}</ref><ref>{{Cite journal|last=Wan|first=Youzhong|last2=Wu|first2=Catherine J.|date=2013-06-06|title=SF3B1 mutations in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/23568491|journal=Blood|volume=121|issue=23|pages=4627–4634|doi=10.1182/blood-2013-02-427641|issn=1528-0020|pmc=3674664|pmid=23568491}}</ref>

+

|<ref name=":20" /> <ref name=":21" /> <ref>{{Cite journal|last=Mitsui|first=Takeki|last2=Koiso|first2=Hiromi|last3=Nakahashi|first3=Hirotaka|last4=Saitoh|first4=Akio|last5=Shimizu|first5=Hiroaki|last6=Ishizaki|first6=Takuma|last7=Ogawa|first7=Yoshiyuki|last8=Takizawa|first8=Makiko|last9=Yokohama|first9=Akihiko|date=2016-02|title=SF3B1 and IGHV gene mutation status predict poor prognosis in Japanese CLL patients|url=https://pubmed.ncbi.nlm.nih.gov/26588928|journal=International Journal of Hematology|volume=103|issue=2|pages=219–226|doi=10.1007/s12185-015-1912-z|issn=1865-3774|pmid=26588928}}</ref> <ref>{{Cite journal|last=Quesada|first=Víctor|last2=Conde|first2=Laura|last3=Villamor|first3=Neus|last4=Ordóñez|first4=Gonzalo R.|last5=Jares|first5=Pedro|last6=Bassaganyas|first6=Laia|last7=Ramsay|first7=Andrew J.|last8=Beà|first8=Sílvia|last9=Pinyol|first9=Magda|date=2011-12-11|title=Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/22158541|journal=Nature Genetics|volume=44|issue=1|pages=47–52|doi=10.1038/ng.1032|issn=1546-1718|pmid=22158541}}</ref> <ref>{{Cite journal|last=Wan|first=Youzhong|last2=Wu|first2=Catherine J.|date=2013-06-06|title=SF3B1 mutations in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/23568491|journal=Blood|volume=121|issue=23|pages=4627–4634|doi=10.1182/blood-2013-02-427641|issn=1528-0020|pmc=3674664|pmid=23568491}}</ref>

|-

|''[[TP53]]''

Line 442: Line 442:

|Established (1)

|

−

|<ref name=":17" /><ref name=":19" /><ref>{{Cite journal|last=Rossi|first=Davide|last2=Khiabanian|first2=Hossein|last3=Spina|first3=Valeria|last4=Ciardullo|first4=Carmela|last5=Bruscaggin|first5=Alessio|last6=Famà|first6=Rosella|last7=Rasi|first7=Silvia|last8=Monti|first8=Sara|last9=Deambrogi|first9=Clara|date=2014-04-03|title=Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/24501221|journal=Blood|volume=123|issue=14|pages=2139–2147|doi=10.1182/blood-2013-11-539726|issn=1528-0020|pmc=4017291|pmid=24501221}}</ref><ref>{{Cite journal|last=Zenz|first=Thorsten|last2=Eichhorst|first2=Barbara|last3=Busch|first3=Raymonde|last4=Denzel|first4=Tina|last5=Häbe|first5=Sonja|last6=Winkler|first6=Dirk|last7=Bühler|first7=Andreas|last8=Edelmann|first8=Jennifer|last9=Bergmann|first9=Manuela|date=2010-10-10|title=TP53 mutation and survival in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/20697090|journal=Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology|volume=28|issue=29|pages=4473–4479|doi=10.1200/JCO.2009.27.8762|issn=1527-7755|pmid=20697090}}</ref><ref>{{Cite journal|last=Stilgenbauer|first=Stephan|last2=Schnaiter|first2=Andrea|last3=Paschka|first3=Peter|last4=Zenz|first4=Thorsten|last5=Rossi|first5=Marianna|last6=Döhner|first6=Konstanze|last7=Bühler|first7=Andreas|last8=Böttcher|first8=Sebastian|last9=Ritgen|first9=Matthias|date=2014-05-22|title=Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial|url=https://pubmed.ncbi.nlm.nih.gov/24652989|journal=Blood|volume=123|issue=21|pages=3247–3254|doi=10.1182/blood-2014-01-546150|issn=1528-0020|pmid=24652989}}</ref>

+

|<ref name=":17" /> <ref name=":19" /> <ref>{{Cite journal|last=Rossi|first=Davide|last2=Khiabanian|first2=Hossein|last3=Spina|first3=Valeria|last4=Ciardullo|first4=Carmela|last5=Bruscaggin|first5=Alessio|last6=Famà|first6=Rosella|last7=Rasi|first7=Silvia|last8=Monti|first8=Sara|last9=Deambrogi|first9=Clara|date=2014-04-03|title=Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/24501221|journal=Blood|volume=123|issue=14|pages=2139–2147|doi=10.1182/blood-2013-11-539726|issn=1528-0020|pmc=4017291|pmid=24501221}}</ref> <ref>{{Cite journal|last=Zenz|first=Thorsten|last2=Eichhorst|first2=Barbara|last3=Busch|first3=Raymonde|last4=Denzel|first4=Tina|last5=Häbe|first5=Sonja|last6=Winkler|first6=Dirk|last7=Bühler|first7=Andreas|last8=Edelmann|first8=Jennifer|last9=Bergmann|first9=Manuela|date=2010-10-10|title=TP53 mutation and survival in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/20697090|journal=Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology|volume=28|issue=29|pages=4473–4479|doi=10.1200/JCO.2009.27.8762|issn=1527-7755|pmid=20697090}}</ref> <ref>{{Cite journal|last=Stilgenbauer|first=Stephan|last2=Schnaiter|first2=Andrea|last3=Paschka|first3=Peter|last4=Zenz|first4=Thorsten|last5=Rossi|first5=Marianna|last6=Döhner|first6=Konstanze|last7=Bühler|first7=Andreas|last8=Böttcher|first8=Sebastian|last9=Ritgen|first9=Matthias|date=2014-05-22|title=Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial|url=https://pubmed.ncbi.nlm.nih.gov/24652989|journal=Blood|volume=123|issue=21|pages=3247–3254|doi=10.1182/blood-2014-01-546150|issn=1528-0020|pmid=24652989}}</ref>

|-

|''[[XPO1]]''

Line 454: Line 454:

|Suspected (2)

|Associated with unmut''IGHV''

−

|<ref>{{Cite journal|last=Cosson|first=A.|last2=Chapiro|first2=E.|last3=Bougacha|first3=N.|last4=Lambert|first4=J.|last5=Herbi|first5=L.|last6=Cung|first6=H.-A.|last7=Algrin|first7=C.|last8=Keren|first8=B.|last9=Damm|first9=F.|date=07 2017|title=Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1|url=https://pubmed.ncbi.nlm.nih.gov/28344316|journal=Leukemia|volume=31|issue=7|pages=1625–1629|doi=10.1038/leu.2017.100|issn=1476-5551|pmid=28344316}}</ref><ref name=":22" /><ref>{{Cite journal|last=Jain|first=Nitin|last2=O'Brien|first2=Susan|date=2015-07-23|title=Initial treatment of CLL: integrating biology and functional status|url=https://pubmed.ncbi.nlm.nih.gov/26065656|journal=Blood|volume=126|issue=4|pages=463–470|doi=10.1182/blood-2015-04-585067|issn=1528-0020|pmc=4624441|pmid=26065656}}</ref>

+

|<ref>{{Cite journal|last=Cosson|first=A.|last2=Chapiro|first2=E.|last3=Bougacha|first3=N.|last4=Lambert|first4=J.|last5=Herbi|first5=L.|last6=Cung|first6=H.-A.|last7=Algrin|first7=C.|last8=Keren|first8=B.|last9=Damm|first9=F.|date=07 2017|title=Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1|url=https://pubmed.ncbi.nlm.nih.gov/28344316|journal=Leukemia|volume=31|issue=7|pages=1625–1629|doi=10.1038/leu.2017.100|issn=1476-5551|pmid=28344316}}</ref> <ref name=":22" /> <ref>{{Cite journal|last=Jain|first=Nitin|last2=O'Brien|first2=Susan|date=2015-07-23|title=Initial treatment of CLL: integrating biology and functional status|url=https://pubmed.ncbi.nlm.nih.gov/26065656|journal=Blood|volume=126|issue=4|pages=463–470|doi=10.1182/blood-2015-04-585067|issn=1528-0020|pmc=4624441|pmid=26065656}}</ref>

|}

<nowiki>*</nowiki>Level 1: present in WHO classification or professional practice guidelines; Level 2: recurrent in well-powered studies with suspected clinical significance; Level 3: recurrent, but uncertain prognostic significance

Kilannin.Krysiak

Editors

120

edits

Changes

CLL Tables: Regions of Recurrent Copy Number Change and CN-LOH (view source)

Revision as of 22:20, 7 November 2020

Navigation menu

Search